A novel means to demonstrate early efficacy of a product in systemic lupus erythematosus

Current Rheumatology Reports

Volumn 9, Issue 6, 2007, Pages 427-430

  Strand, Vibeke ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; BELIMUMAB; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRASTERONE; PREDNISONE;

CLINICAL TRIAL; DISEASE SEVERITY; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; NOTE; PATIENT CARE; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 37349001982     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0069-z     Document Type: Note

References (29)

1. Strand V: Issues in drug development in SLE: clinical trial design, outcome measures and biomarkers. In Dubois' Lupus Erythematosus, 7th edn. Edited by Wallace DJ, Hahn GH. Baltimore: Williams & Wilkins; 2006:1317-1332.
2. Strand V, Kimberly R, Isaacs JD: Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007, 6:1-18.
3. Strand V: Lessons learned from clinical trials in SLE. Autoimmun Rev 2007, 6:209-214.
4. Kalunian KC, Davis JC Jr, Merrill JT, et al.: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD 154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258.
5. Gordon C, Sutcliffe N, Skan J, et al.: Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003, 42:1372-1379.
6. Alarcon-Segovia D, Tumlin JA, Furie RA, et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus:results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003, 48:442-444.
7. Linnik MD, Hu JZ, Heilbrunn KR, et al.: Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:1129-1137.
8. Buyon JP, Petri M, Kim MY, et al.: The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann intern Med 2005, 142:953-962.
9. Petri M, Kim MY, Kalunian KC, et al.: Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005, 353:2550-2558.
10. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al.: A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005, 353:2539-2549.
11. Furie R, Lisse J, Merrill JT, et al.: Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLyS] improves or stabilizes SLE activity in a multicenter phase 2 trial. Arthritis Rheum 2006, 54:S258.
12. Swaak AJ, Groenwold J, Bronsveld W, et al.: Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986, 45:359-366.
13. TerBorg EJ, Horst G, Hummel EJ, et al.: Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990, 33:634-643.
14. Bootsma H, Spronk P, Derksen R, et al.: Prevention of relapses in systemic lupus erythematosus. Lancet 1995, 345:1595-1599.
15. Bijl M, Horst G, Bootsma H, et al.: Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003: 62:534-539.
16. Gladman DD, Urowitz MB, Keystone EC: Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979, 66:210-215.
17. Tseng CE, Buyon JP, Kim M, et al.: The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:3623-3632.
18. Thumboo J, Strand V: Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore 2007, in press.
19. Petri MA, Mease PJ, Merrill JT, et al.: Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 2004, 50:2858-2868.
20. Nordmark G, Bengtsson C, Larsson A, et al.: Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity 2005, 38:531-540.
21. Tse KC, Tang CS, Lio WL, et al.: Quality of life comparison between corticosteroid and-mycophenolate mofetil and corticosteroid and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 2006, 15:371-379.
22. Strand V, Aranow C, Cardiel MH, et al.: Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003, 12:677-686.
23. Strand V, Crawford B: Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoeconomics Outcomes Res 2005, 5:317-326.
24. Strand V, Crawford B, Petri M, et al.: Patients with active systemic lupus erythematosus (SLE) treated with belimumab improve health-related quality of life (HRQoL) in a randomized controlled trial (RCT). Arthritis Rheum 2006, 54:S277.
25. Strand V, Crawford B, Petri M, et al.: Therapeutic responses reflecting a reduction in SELENA SLEDAI score are associated with a stabilization or improvement in health-related quality of life (HRQoL). Arthritis Rheum 2006, 54:S278.
26. Petri M, Buyon J, Sigler L, et al.: Beneficial effects of hormone therapy on health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE): Results of SELENA OCP and HRT randomized controlled trials (RCTs). Arthritis Rheum 2006, 54:S447
27. Strand V, Petri M, Buyon J, et al.: Baseline data from 5 randomized controlled trials (RCTs) demonstrated that SLE impacts all domains of health-related quality of life (HRQoL). Arthritis Rheum 2006, 54:S277.
28. Kirou KA, Lee C, George S, et al.: Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503.
29. Petri M, Stohl W, Chatham W, et al.: BLyS plasma concentrations correlate with disease activity and levels of Anti-dsDNA autoantibodies and immunoglobulins (Ig) in a SLE patient observational study. Arthritis Rheum 2003, 48:S655.